Ratings of the last 12 months
This list shows every rating MEQIRI has published for a stock, an ETF or a coin, and every change between Strong, Neutral and Weak. For stocks it also shows every valuation signal and its changes.
Counted from the public launch on 7 Nov 2026.
- Price target: none, MEQIRI does not give price targets.
- Fair value: for the valuation signal, that day's fair value, converted like the price. An estimate from the disclosed model, not a price target.
- Validity: until the rating or the valuation signal changes, time horizon about 12 months, recalculated every night.
- Price: last close before publication, converted into dollars at that day's ECB rate; ETFs in euros.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
4 entries
- Eton Pharmaceuticals, Inc.13 Nov 2026Strong (Before Neutral), Score 70, $61.45
- Eton Pharmaceuticals, Inc.10 Nov 2026Neutral (Before Strong), Score 69, $64.35
- Eton Pharmaceuticals, Inc.7 Nov 2026Strong (first rating), Score 70, $56.46
- Eton Pharmaceuticals, Inc.7 Nov 2026Valuation signal Fairly valued (first signal), Fair value $83.25, $56.46
| Date | Security | Rating | Before | Score | Fair value | Price |
|---|---|---|---|---|---|---|
| 13 Nov 2026 | Eton Pharmaceuticals, Inc. ETON | Strong | Neutral | 70 | $61.45 | |
| 10 Nov 2026 | Eton Pharmaceuticals, Inc. ETON | Neutral | Strong | 69 | $64.35 | |
| 7 Nov 2026 | Eton Pharmaceuticals, Inc. ETON | Strong | first rating | 70 | $56.46 | |
| 7 Nov 2026 | Eton Pharmaceuticals, Inc. ETON | Valuation signalFairly valued | first signal | $83.25 | $56.46 |
Legal basis: Article 4(1)(i) of Delegated Regulation (EU) 2016/958.
To the disclosures